Drug Profile
Research programme: antibody therapeutics - Adimab/Kyowa Kirin
Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Adimab; Kyowa Hakko Kirin
- Developer Adimab; Kyowa Kirin
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 07 Jan 2013 Early research in Undefined indication in USA (Parenteral)